Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Palbociclib|DRUG: AI
Sponsor: Zhejiang Cancer Hospital
Collaborators: Pfizer